+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Sinusitis Treatment Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 160 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5805804
The global market value was USD 3.2 billion in 2022 and is anticipated to grow at a CAGR of 3.8% during the forecast period of 2023-2031, driven by the growing prevalence of sinusitis across the globe. The global sinusitis treatment market share is anticipated to achieve a value of USD 4.4 billion by 2031.

Sinusitis Treatment Market: Introduction

Sinusitis is a common condition that occurs when the tissues lining the sinuses become swollen and inflamed. It can cause a range of symptoms, including nasal congestion, headache, facial pain, and fever. Sinusitis can be acute or chronic, and can be caused by a variety of factors, including bacterial, viral, or fungal infections, allergies, or structural issues in the sinuses.

Treatment for sinusitis typically involves medication to reduce inflammation and manage symptoms, such as pain relievers and decongestants. In some cases, antibiotics may be prescribed if the condition is caused by a bacterial infection. Other treatment options may include nasal sprays, saline rinses, and in severe cases, surgery to remove blockages in the sinuses.

The global market for sinusitis treatment is expected to experience steady growth in the coming years, driven by a growing prevalence of sinusitis worldwide and an increasing awareness of the condition and its treatment options. Technological advancements in diagnostic tools and treatment options are also expected to contribute to market growth, as are the increasing availability of over-the-counter sinusitis medications and a growing demand for minimally invasive surgical procedures. However, factors such as the high cost of treatment and the risk of side effects associated with some medications may limit market growth in certain regions.

Key Trends in the Market

Some key trends in the global sinusitis treatment market are:
  • Increasing prevalence of sinusitis: The increasing prevalence of sinusitis due to factors such as allergies, air pollution, and respiratory infections is driving the demand for sinusitis treatment
  • Growing preference for minimally invasive procedures: The growing preference for minimally invasive procedures among patients is fuelling the demand for endoscopic sinus surgery and balloon sinuplasty procedures
  • Technological advancements in sinusitis treatment: The development of advanced imaging techniques, surgical instruments, and drugs for the treatment of sinusitis is expected to drive market growth
  • Increasing demand for antibiotics: The increasing demand for antibiotics for the treatment of sinusitis is expected to drive market growth. However, the overuse of antibiotics has led to the development of antibiotic resistance, which is a major concern for the market
  • Increasing adoption of telemedicine: The increasing adoption of telemedicine for the diagnosis and treatment of sinusitis is expected to drive market growth. Telemedicine allows patients to receive care remotely, which is particularly useful for patients who live in remote areas or who have difficulty traveling to a healthcare facility

Sinusitis Treatment Market Segmentations

The market can be categorised into the following segments:

Market Breakup by Treatment

  • Analgesics
  • Antihistamines
  • Corticosteroids
  • Antibiotics
  • Sulphonamides
  • Quinolones
  • Surgery
  • Others

Market Breakup by Disease Type

  • Acute Sinusitis
  • Subacute Sinusitis
  • Chronic Sinusitis

Market Breakup by Route of Administration

  • Topical
  • Oral
  • Nasal
  • Injectable

Market Breakup by End User

  • Hospitals
  • Homecare
  • Speciality Clinics
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Market Breakup by Regions

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Sinusitis Treatment Market Scenario

  • The global sinusitis treatment market is expected to grow significantly in the coming years. The market growth is primarily driven by the increasing prevalence of sinusitis, technological advancements in diagnosis and treatment methods, and the growing awareness among patients regarding sinusitis and its treatment options
  • The increasing prevalence of acute and chronic sinusitis, coupled with the rising demand for minimally invasive surgical procedures, is expected to boost market growth in the forecast period
  • In addition, the availability of advanced diagnostic techniques such as CT scan, MRI, and nasal endoscopy, is expected to drive the demand for effective treatment options. Moreover, the increasing availability of over the counter (OTC) drugs and the growing popularity of self-medication are expected to further fuel market growth
  • North America dominated the global sinusitis treatment market in 2020, owing to the high prevalence of sinusitis in the region and the availability of advanced treatment options. However, the Asia Pacific region is expected to witness significant growth in the coming years due to the rising prevalence of sinusitis and increasing healthcare expenditure in the region
Competitive Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Pfizer Inc
  • Merck KGaA
  • Sanofi
  • Biocare Medical, LLC
  • Teva Pharmaceutical Industries
  • Bristol-Myers Squibb Company
  • GSK plc
  • Bayer AG
  • AstraZeneca
  • Regeneron Pharmaceuticals Inc
  • OptiNose US, Inc

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Sinusitis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Sinusitis Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Sinusitis Epidemiology (2016-2031)
5.3 Europe Sinusitis Epidemiology (2016-2031)
5.4 Asia-Pacific Sinusitis Epidemiology (2016-2031)
5.5 Latin America Sinusitis Epidemiology (2016-2031)
5.6 Middle East & Africa Sinusitis Epidemiology (2016-2031)
6 Global Sinusitis Treatment Market Overview
6.1 Global Sinusitis Treatment Market Historical Value (2016-2022)
6.2 Global Sinusitis Treatment Market Forecast Value (2023-2031)
7 Global Sinusitis Treatment Market Landscape
7.1 Sinusitis Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Sinusitis Treatment: Product Landscape
7.2.1 Analysis by Treatment
7.2.2 Analysis by Disease Type
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by End User
7.2.5 Analysis by Distribution Channel
8 Sinusitis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Sinusitis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Sinusitis Treatment Market Segmentation
11.1 Global Sinusitis Treatment Market by Treatment
11.1.1 Market Overview
11.1.2 Analgesics
11.1.3 Antihistamines
11.1.4 Corticosteroids
11.1.5 Antibiotics
11.1.6 Sulphonamides
11.1.7 Quinolones
11.1.8 Surgery
11.1.9 Others
11.2 Global Sinusitis Treatment Market by Disease Type
11.2.1 Market Overview
11.2.2 Acute Sinusitis
11.2.3 Subacute Sinusitis
11.2.4 Chronic Sinusitis
11.3 Global Sinusitis Treatment Market by Route of Administration
11.3.1 Market Overview
11.3.2 Topical
11.3.3 Oral
11.3.4 Nasal
11.3.5 Injectable
11.4 Global Sinusitis Treatment Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Homecare
11.4.4 Specialty Clinics
11.4.5 Others
11.5 Global Sinusitis Treatment Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacies
11.5.3 Retail Pharmacies
11.5.4 Online Pharmacies
11.6 Global Sinusitis Treatment Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Sinusitis Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Sinusitis Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Sinusitis Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Sinusitis Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Sinusitis Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Pfizer Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Merck KGaA
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Sanofi
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Biocare Medical, LLC
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Teva Pharmaceutical Industries
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Bristol-Myers Squibb Company
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 GSK plc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Bayer AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 AstraZeneca
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Regeneron Pharmaceuticals Inc
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 OptiNose US, Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Sinusitis Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Pfizer Inc.
  • Merck KGaA
  • Sanofi
  • Biocare Medical LLC
  • Teva Pharmaceutical Industries
  • Bristol-Myers Squibb Company
  • GSK plc.
  • Bayer AG
  • AstraZeneca
  • Regeneron Pharmaceuticals Inc
  • OptiNose US Inc.

Methodology

Loading
LOADING...

Table Information